19 Jul 1st Trials of Moderna’s Covid-19 Vaccine Positive
We curated this piece by Olivia Rosane from EcoWatch to, um, inject a positive note into your upcoming week.
Results from the Phase 1 trial of Cambridge, Massachusetts biotech firm Moderna’s coronavirus vaccine show it is safe and produces an immune response.
The preliminary report of the trial, published in The New England Journal of Medicine on Tuesday, reveals that all 45 participants developed so-called neutralizing antibodies that bind to the virus and stop it from attacking other cells. They developed these antibodies at levels comparable to the upper half of COVID-19 survivors.
“The good news is that this vaccine induced antibodies,” director of the National Institute of Allergy and Infectious Diseases Anthony Fauci told Bloomberg News. “Not just any kind of antibodies, but neutralizing antibodies.”
Public health experts agree that a vaccine is necessary to return life to normal in the wake of a pandemic that has infected millions and killed almost 575,000, according to Reuters. More than one vaccine will probably be required, because it will be difficult for any one company to produce the billions of doses needed, The New York Times pointed out.
“None of us are safe unless all of us are safe,” Columbia University virologist Dr. Angela Rasmussen told The New York Times. “It’s not just us. It’s everybody in the world.”
The Moderna vaccine candidate was the first to be tested on human subjects, and Tuesday’s published paper confirms the positive results reported by the company in May…
Sorry, the comment form is closed at this time.